|
Beurs gesloten -
Andere beurzen
|
Nabeurs 18:22:07 | |||
| 0,6120 EUR | +13,12% |
|
0,6120 | 0,00% |
| 13/07 | AB Science staakt drie klinische studies met masitinib | MT |
| 10/07 | AB Science rationaliseert portefeuille en focust op twee moleculen |  |
Belangrijkste concurrenten
Toevoegen aan een lijst 0 geselecteerde | Verschil (%) | Varia. 5d. | Evolutie 1 maand | Evolutie 3 maanden | Var. 1 jan | Varia. 1j. | Varia. 3j. | Varia. 5j. | Varia. 10j. | Kap.($) | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 | +13,12% | -12,32% | -20,83% | -38,80% | -60,16% | -55,13% | -82,44% | -94,87% | -95,58% | 49,8 mln. | |
| -2,40% | -2,66% | +0,39% | +12,53% | +20,92% | +59,38% | +20,38% | +66,58% | +120,78% | 322 mld. | |
| -0,49% | +0,49% | -2,20% | +30,21% | +16,19% | +31,65% | -13,19% | -18,41% | +44,94% | 71,6 mld. | |
| -0,09% | +1,36% | +2,24% | +27,91% | +22,72% | +37,67% | +96,18% | +104,94% | +694,90% | 9,79 mld. | |
| -1,53% | -3,92% | -4,39% | +5,08% | -0,46% | -2,67% | -7,72% | -29,73% | +43,83% | 8,39 mld. | |
| -0,76% | -2,73% | -9,47% | -21,52% | -37,08% | -16,42% | -13,85% | -36,77% | - | 4,3 mld. | |
| +0,14% | -1,74% | +4,99% | -19,65% | -34,52% | -34,69% | +6,15% | +37,42% | +80,63% | 3,81 mld. | |
| -2,35% | -3,72% | -16,44% | +8,11% | +20,26% | -14,99% | +13,09% | -37,27% | - | 3,58 mld. | |
| +7,52% | +3,43% | +2,86% | -0,08% | -2,23% | +31,15% | +52,56% | +80,70% | +112,00% | 2,59 mld. | |
| +0,47% | +10,40% | +1,38% | -10,89% | -11,96% | +0,22% | -2,76% | +72,73% | - | 2,25 mld. | |
| +0,90% | +5,31% | +0,79% | -6,99% | -11,68% | -21,69% | -13,90% | -4,70% | -39,42% | 1,76 mld. | |
| -2,08% | -8,12% | -8,64% | -17,27% | -11,33% | -30,81% | +16,98% | -34,14% | - | 1,74 mld. | |
| -.--% | -.--% | - | - | - | - | - | - | - | 1,64 mld. | |
| -3,15% | +4,54% | +16,33% | +46,65% | +161,56% | +207,37% | +1.621,01% | +661,27% | - | 1,27 mld. | |
| +10,68% | +21,15% | +7,58% | -25,54% | -27,52% | +76,96% | +66,79% | +43,52% | +550,83% | 1,26 mld. | |
| +4,08% | +1,72% | -14,42% | -31,73% | -19,60% | -51,32% | -27,37% | - | - | 1,1 mld. | |
| -5,63% | -8,87% | -5,86% | -10,76% | -17,10% | -12,49% | +9,52% | +67,39% | +58,97% | 1,06 mld. | |
| -3,28% | -13,80% | -37,36% | -18,20% | -5,15% | -20,48% | +57,79% | -16,53% | - | 982 mln. | |
| +1,07% | +8,26% | +2,87% | -17,06% | -20,10% | -35,54% | -73,58% | -82,54% | - | 913 mln. | |
| 0,00% | +2,98% | -0,41% | -14,79% | -12,95% | -41,97% | -11,03% | -48,40% | -66,15% | 866 mln. | |
| Gemiddelde | +0,89% | +1,40% | -4,24% | -5,41% | -1,59% | +5,59% | +90,24% | +40,62% | +136,88% | 22,03 mld. | |
| Gewogen gemiddelde per kap. | -1,56% | +0,02% | -0,36% | +14,21% | +18,02% | +49,31% | +19,90% | +49,92% | +119,34% |
Kies jouw editie
Alle financiële informatie op nationaal niveau
